RESUMO
Diesel particulate matter (DPM) is a common and well-known health hazard in the mining environment. The regulatory method for monitoring both the organic and elemental carbon (OC, EC) portions of DPM is a laboratory-based thermal-optical method with a typical turnaround time of one week. In order to evaluate exposure levels and take corrective action prior to overexposure, a portable real-time device capable of quantifying both OC and EC is needed. To that end, researchers from the National Institute for Occupational Safety and Health (NIOSH) designed and tested the feasibility of a device based on bandpass optical filters that target key infrared wavelengths associated with DPM and its spectroscopic baseline. The resulting device, referred to here as a non-dispersive infrared (NDIR) spectrometer could serve as the basis of a cost-effective, field-portable alternative to the laboratory thermal-optical method. The limits of quantification (LOD) indicate that the NDIR spectrometer can quantify EC, OC, and TC provided they are present at 20, 37, and 46 µg/m3 or more, respectively. In the event that the NDIR spectrometer is integrated with a sampler and filter tape the LOD is estimated to be reduced to 13, 7, and 10 µg/m3 for EC, OC, and TC, respectively. These LOD estimates assume a face velocity of 59 cm/s and a sampling time of 30 min.
RESUMO
A method for the quantification of airborne organic carbon (OC) and elemental carbon (EC) within aerosolized diesel particulate matter (DPM) is described in this article. DPM is a known carcinogen encountered in many industrial workplaces (notably mining) and in the ambient atmosphere. The method described here collects DPM particles onto a quartz fiber filter, after which reflection-mode infrared spectra are measured on a mid-infrared Fourier transform (FT-IR) spectrometer. Several infrared absorption bands are investigated for their efficacy in quantifying OC and EC. The thermo-optical (T-O) method is used to calibrate a linear regression model to predict OC and EC from the infrared spectra. The calibrated model, generated from laboratory DPM samples, is then utilized to quantify OC and EC in mine samples obtained from two metal mine locations under a variety of operating conditions. The feasibility of further improving these results by partial least squares (PLS) regression was investigated. A single calibration that is broadly applicable would be considered an improvement over currently available portable instruments, which require aerosol-specific calibration.
RESUMO
PURPOSE: Evaluate how reducing ritonavir (RTV) boosting from 200 mg to 100 mg once daily (QD) affects steady-state pharmacokinetics of components of a fosamprenavir (FPV)-based regimen. METHODS: Prospective, open-label, pharmacokinetic study in 12 HIV-infected patients stabilized on FPV/RTV 1400 mg/200 mg + tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) 300 mg/200 mg QD (TELEX II). Pharmacokinetics were assessed by noncompartmental analysis at baseline and 4 weeks after RTV reduction to 100 mg QD. RESULTS: Baseline median minimum plasma concentration (Cmin) and area under the plasma concentration-time curve over 24 hours post dose (AUC24h) were as follows: APV: 1,708 ng/mL, 84,260 h * ng/mL; tenofovir: 53 ng/mL, 2,420 h * ng/mL; FTC: 58 ng/mL, 9,190 h * ng/mL; RTV: 80 ng/mL, 10,230 h * ng/mL. Four weeks after reducing RTV, changes in Cmin and AUC24h were: APV: +26%, +0.6%; tenofovir: +77%, +30%; FTC: +188%, +13%; RTV -64%, -79%. Component plasma concentration ranges were consistent with historical values. Median APV Cmin was 14.7-fold above the protein-binding-adjusted 50% inhibitory concentration of wild-type HIV. Four weeks after RTV reduction, HIV-1 RNA levels remained <50 copies/mL in all patients, median CD4+ count increased from 465 to 495 cells/mm3, and favorable lipid changes and no adverse events were observed. CONCLUSION: Reducing RTV boosting from 200 to 100 mg QD of FPV/TDF/FTC QD conferred no detrimental effect on APV, tenofovir, FTC, or RTV pharmacokinetics and maintained virologic suppression.
Assuntos
Antivirais/administração & dosagem , Antivirais/farmacocinética , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , Adenina/administração & dosagem , Adenina/análogos & derivados , Adenina/farmacocinética , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/farmacocinética , Antivirais/sangue , Antivirais/normas , Contagem de Linfócito CD4 , Carbamatos/administração & dosagem , Carbamatos/farmacocinética , Cromatografia Líquida de Alta Pressão , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Desoxicitidina/farmacocinética , Combinação de Medicamentos , Emtricitabina , Feminino , Furanos , Infecções por HIV/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Organofosfatos/administração & dosagem , Organofosfatos/farmacocinética , Organofosfonatos/administração & dosagem , Organofosfonatos/farmacocinética , Estudos Prospectivos , RNA Viral , Ritonavir/administração & dosagem , Ritonavir/farmacocinética , Sulfonamidas/administração & dosagem , Sulfonamidas/farmacocinética , Tenofovir , Carga ViralRESUMO
HAART has decreased the incidence of AIDS and death among HIV-infected individuals dramatically. This approach often becomes cumbersome to patients, involving multiple drugs administered on varying schedules. We investigated the pharmacokinetics, efficacy, and tolerability of a once-daily regimen of fosamprenavir, tenofovir, emtricitabine and ritonavir in HIV-infected treatment-naive subjects. No clinically significant interaction between the drugs was noted, and the regimen showed good efficacy and tolerability over the course of 48 weeks.
Assuntos
Antivirais/farmacocinética , Infecções por HIV/tratamento farmacológico , Adenina/administração & dosagem , Adenina/análogos & derivados , Adenina/sangue , Adenina/farmacocinética , Adolescente , Adulto , Antivirais/administração & dosagem , Antivirais/sangue , Carbamatos/administração & dosagem , Carbamatos/sangue , Carbamatos/farmacocinética , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Desoxicitidina/sangue , Desoxicitidina/farmacocinética , Esquema de Medicação , Quimioterapia Combinada , Emtricitabina , Furanos , Infecções por HIV/sangue , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/sangue , Inibidores da Protease de HIV/farmacocinética , Humanos , Organofosfatos/administração & dosagem , Organofosfatos/sangue , Organofosfatos/farmacocinética , Organofosfonatos/administração & dosagem , Organofosfonatos/sangue , Organofosfonatos/farmacocinética , RNA Viral/análise , Inibidores da Transcriptase Reversa/administração & dosagem , Inibidores da Transcriptase Reversa/sangue , Inibidores da Transcriptase Reversa/farmacocinética , Ritonavir/administração & dosagem , Ritonavir/sangue , Ritonavir/farmacocinética , Sulfonamidas/administração & dosagem , Sulfonamidas/sangue , Sulfonamidas/farmacocinética , Tenofovir , Resultado do TratamentoRESUMO
For practical use in harsh radiation environments, we pose selection criteria for piezoelectric materials for non-destructive evaluation (NDE) and material characterization. Using these criteria, piezoelectric aluminum nitride is shown to be an excellent candidate. The results of tests on an aluminum-nitride- based transducer operating in a nuclear reactor are also presented. We demonstrate the tolerance of single-crystal piezoelectric aluminum nitride after fast and thermal neutron fluences of 1.85 x 10(18) neutron/cm(2) and 5.8 x 10(18) neutron/ cm(2), respectively, and a gamma dose of 26.8 MGy. The radiation hardness of AlN is most evident from the unaltered piezoelectric coefficient d33, which measured 5.5 pC/N after a fast and thermal neutron exposure in a nuclear reactor core for over 120 MWh, in agreement with the published literature value. The results offer potential for improving reactor safety and furthering the understanding of radiation effects on materials by enabling structural health monitoring and NDE in spite of the high levels of radiation and high temperatures, which are known to destroy typical commercial ultrasonic transducers.